ArticleActa pharmacologica Sinica2020

Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy.

Xu-Yong Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.